[ad_1]
-
The TOTUM•63 action model clinical study was jointly designed by the Valbiotis team, INAF experts and Nestlé Health Sciences experts as part of the global strategic partnership with Nestlé Health Sciences.
-
The study will explore the role of TOTUM•63 in the human body and provide additional data to support the scientific communication and commercialization of the active substance in the pre-diabetes market.
-
Its launch time is set at 4day In the fourth quarter of 2021 in Canada. André MARETTE, a professor at the Faculty of Medicine of the University of Laval and a researcher at INAF, will serve as the scientific advisor.
Regulatory News:
Valbiotis (FR0013254851-ALVAL, PEA/SME qualified), a scientific and innovative research and development company dedicated to preventing and fighting metabolic diseases, announced the implementation of the TOTUM•63 Action Mode Clinical Study (INAF) in Quebec City by the Institute of Nutrition and Functional Foods. Val University collaborates with Nestlé Health Sciences.
As part of a global strategic partnership, the study designed by Valbiotis, INAF and Nestlé health science experts will include 20 volunteers and will explore the mechanism of TOTUM•63 in humans. It will provide more data to strengthen scientific communication and support the commercialization of TOTUM•63.Expected to start on the 4thday In the first quarter of 2021, it will be conducted under the scientific supervision of André MARETTE, a professor at Laval University School of Medicine and an INAF researcher.
Board member Valbiotis Chief Medical, Regulatory and Industrial Affairs Officer Murielle CAZAUBIEL commented: “This ambitious study will explore the mode of action of TOTUM•63 (a multi-target active substance) in the human body. This is the result of a high-level collective collaboration with INAF and Nestlé health science experts. We would like to thank them for thanking them Commitment to this process. INAF is a key participant in the field of nutrition and metabolic science in North America, especially in Canada, a country that is in a leading position in the regulation of natural health products. This cooperation is an undeniable asset for completing TOTUM• 63. Development under a global strategic partnership with Nestlé Health Sciences. This affiliation with the Canadian science ecosystem reflects our commitment to developing R&D activities in North America, which is a global research center and a leader in the field of metabolic diseases Commercial market.”
TOTUM•63 mode of action clinical research will explore the main mode of action hypothesis produced by preclinical work in humans. It will include 20 overweight or obese volunteers with related metabolic abnormalities. The agreement has a number of scientific goals and will evaluate…
The full story on Benzinga.com
[ad_2]
Source link
